BioSpace News Archive

The Honduran government and the private sector joined efforts and resources to work as a team to confront COVID-19.

ZOLL® Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, is taking aggressive steps to increase manufacturing capacity to 10,000 ventilators per month in response to the COVID-19 pandemic.

CEL-SCI Corporation announced that it has entered into an underwriting agreement with Aegis Capital Corp. under which the underwriter has agreed to purchase on a firm commitment basis a minimum of 500,000 shares of common stock of the Company, at a price to the public of $12.22 per share, representing a 5% discount to the closing price per share.

Ufovax, a spin-off vaccine company from Scripps Research, announced that the company has successfully extended its patented one component self-assembling protein nanoparticle vaccine platform technology to a vaccine against the coronavirus SARS-CoV-2.

Oncopeptides AB announced the publication of results from its O-12-M1 study, melflufen plus dexamethasone in relapsed/refractory multiple myeloma, a multicenter, international, open-label, phase 1/2 study in The Lancet Haematology.

The U.S. Food and Drug Administration took the following actions in our ongoing response effort to the COVID-19 pandemic

EpimAb Biotherapeutics announced the appointment of Dr. Xinyi “David” Gu as the new Chief Financial Officer of EpimAb, adding to the current leadership team consisting of Chengbin Wu, Ph.D. CEO; Stephan Lensky, Ph.D. COO and CBO; and Bin Peng, M.D., Ph.D., CMO. Dr. Gu joins EpimAb from Millennium Management where he oversaw investments in global pharmaceutical and biotechnology companies.

70+ StartX Med Innovators with Medical Breakthroughs for the Prevention, Diagnostics and Treatment of Coronavirus Mobilize Efforts to Fast-Track Public Health Needs During Pandemic

Company Benefits from Unique Chinese, Hong Kong, Macau Diagnostic Patent Rights, and Closes Deal to Help America Now